Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacc 10 intranasal vaccine in healthy volunteers
NCT05604690Phase 1Completed
- Sponsor
- Intravacc
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Avacc 10 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Intravacc. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 3 more. Started Nov 2022; status: completed.
02
Drugs
Avacc 10
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05604690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604690.